Veritas will participate in the MENA Organization for Rare Diseases Annual Meeting to be held in Dubai from March 3 to 5
Veritas will participate in the event, where it will showcase its advanced diagnostic and genetic counseling portfolio that allows the identification of rare diseases from the most appropriate medical approach.
300 million people in the world live with a rare disease, which accounts for 5% of the European population and is estimated to affect 3 in every 10 pregnancies.
Newborn genetic screening is key in the early diagnosis of a rare disease, taking into account that 75% of patients are children, and that the average time to diagnosis is 4 years, this period increasing to 10 years for 20% of patients.
The Veritas genetic diagnostic portfolio is based on whole exome or genome sequencing, which is of great interest in the case of patients with complex medical history or symptoms suggestive of genetic disease, even where other tests have produced negative results.
Veritas will be attending the MENA Organization for Rare Diseases Annual Meeting to be held in Dubai (UAE) from March 3 to 5, 2023, https://menararediseases.com.
The conference, which takes advantage of the visibility given by the recently celebrated World Rare Disease Day (February 28), is the largest event held in the region on this type of pathologies. More than 100 speakers will present the latest updates through presentations, symposiums and workshops related to rare diseases in various clinical fields, such as cardiology, pneumology, neurology, oncology, metabolism, endocrinology, immunology, pediatrics and genetics.
Veritas will participate in the event with a booth where it will showcase its advanced portfolio of genetic diagnostics and perinatal medicine, which allow the identification of different rare diseases, thus providing the best therapeutic approach.
“The main challenge in the field of rare diseases remains diagnosis. It is therefore paradoxical that the use of newborn genetic screening, which in a large number of cases would allow early diagnosis and better treatment and prognosis of these patients, is not standardized” -says Dr. Izquierdo- “Participation in events such as the MENA Organization for Rare Diseases Annual Meeting, which brings together professionals, companies and patients, is essential to disseminate the tools we already have and the latest advances in this field,” concludes Dr. Izquierdo, who, in addition to being Chief Medical Officer of Veritas, has extensive experience in clinical genetics.
Published on: 3 March 2023 | Source: www.veritasint.com